Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

August 19, 2024

Study Completion Date

January 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

Trial Locations (88)

8

GSK Investigational Site, Dublin

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

404

GSK Investigational Site, Taichung

704

GSK Investigational Site, Tainan City

1414

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

2170

GSK Investigational Site, Liverpool

2298

GSK Investigational Site, Newcastle

3002

GSK Investigational Site, East Melbourne

3010

GSK Investigational Site, Bern

5011

GSK Investigational Site, Woodville

10065

GSK Investigational Site, New York

10210

GSK Investigational Site, Bangkok

10330

GSK Investigational Site, Bangkok

11528

GSK Investigational Site, Athens

12462

GSK Investigational Site, Athens

15121

GSK Investigational Site, Alessandria

16132

GSK Investigational Site, Genova

17007

GSK Investigational Site, Girona

17475

GSK Investigational Site, Greifswald

22763

GSK Investigational Site, Hamburg

26504

GSK Investigational Site, Rio Patras

33011

GSK Investigational Site, Oviedo

33401

GSK Investigational Site, West Palm Beach

37203

GSK Investigational Site, Nashville

37404

GSK Investigational Site, Chattanooga

40002

GSK Investigational Site, Khon Kaen

40705

GSK Investigational Site, Taichung

42123

GSK Investigational Site, Reggio Emilia

44124

GSK Investigational Site, Ferrara

45100

GSK Investigational Site, Orléans

46010

GSK Investigational Site, Valencia

47014

GSK Investigational Site, Meldola FC

47900

GSK Investigational Site, Rimini

49241

GSK Investigational Site, Pusan

50200

GSK Investigational Site, Chiang Mai

58128

GSK Investigational Site, Hwasun

63100

GSK Investigational Site, Ascoli Piceno

64114

GSK Investigational Site, Kansas City

77090

GSK Investigational Site, Houston

84902

GSK Investigational Site, Avignon

140044

GSK Investigational Site, Córdoba

380009

GSK Investigational Site, Ahmedabad

400071

GSK Investigational Site, Sushrut Hospital and Research

411004

GSK Investigational Site, Pune

422005

GSK Investigational Site, Apex Wellness Hospital

500033

GSK Investigational Site, Hyderabad

560054

GSK Investigational Site, M S R Nagar Msrit Post

700014

GSK Investigational Site, Kolkata

700156

GSK Investigational Site, Kolkata

C1181ACH

GSK Investigational Site, Buenos Aires

C1426ANZ

GSK Investigational Site, Capital Federal

B1629AHJ

GSK Investigational Site, Pilar

S2002

GSK Investigational Site, Rosario

89201-260

GSK Investigational Site, Joinville

90850-170

GSK Investigational Site, Porto Alegre

22271-110

GSK Investigational Site, Rio de Janeiro

41253-190

GSK Investigational Site, Salvador

01236-030

GSK Investigational Site, São Paulo

04537-080

GSK Investigational Site, São Paulo

L1G 2B9

GSK Investigational Site, Oshawa

M5G 2M9

GSK Investigational Site, Toronto

H4J 1C5

GSK Investigational Site, Montreal

06189

GSK Investigational Site, Nice

03048

GSK Investigational Site, Cottbus

01307

GSK Investigational Site, Dresden

106 76

GSK Investigational Site, Athens

D09 V2N0

GSK Investigational Site, Dublin

09121

GSK Investigational Site, Cagliari

03100

GSK Investigational Site, Mexico City

03720

GSK Investigational Site, Mexico City

85-168

GSK Investigational Site, Bydgoszcz

80-214

GSK Investigational Site, Gdansk

40-519

GSK Investigational Site, Katowice

20-081

GSK Investigational Site, Lublin

60-569

GSK Investigational Site, Poznan

87-100

GSK Investigational Site, Torun

02-781

GSK Investigational Site, Warsaw

58-309

GSK Investigational Site, Wałbrzych

50-367

GSK Investigational Site, Wroclaw

03080

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

02006

GSK Investigational Site, Albacete

08026

GSK Investigational Site, Barcelona

08221

GSK Investigational Site, Terrassa - Barcelona

LE1 5WW

GSK Investigational Site, Leicester

W12 0HS

GSK Investigational Site, London

ST4 6QG

GSK Investigational Site, Stoke-on-Trent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05064358 - Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter